Severe acute otitis media and mastoiditis caused by group A beta-hemolytic streptococcus

Juha T. Laakso MD1 | Valtteri Rissanen MD1 | Eeva Ruotsalainen MD, PhD2 | Jarkko Korpi MD, PhD1 | Anu Laulajainen-Hongisto MD, PhD1 | Ville Sivonen DSc1 | Saku T. Sinkkonen MD, PhD1

Abstract

Objective: To describe the characteristics, diagnostics, treatment, and outcome of severe acute otitis media (AOM) and acute mastoiditis (AM) caused by group A beta-hemolytic streptococcus (GAS).

Study design: A retrospective cohort study.

Methods: The yearly incidence of inpatient care-needing GAS AOM/AM patients in our hospital catchment area between 2002 and 2018 was investigated. A detailed analysis was performed for cases treated during the last GAS epidemic in 2017-2018. Anamnesis, signs and symptoms, pure-tone audiometry results, treatment, complications, and outcome were collected from medical charts. Patients responded to an otology-specific health-related quality of life survey (EOS-16) 1.5 to 3 years after their treatment.

Results: The number of GAS infections peaks at approximately 7-year intervals. During 2017 and 2018, altogether 37 patients (29 adults and 8 children) were hospitalized due to GAS AOM/AM. AM was diagnosed in 14 (38%) patients. The disease progression was typically very rapid. At presentation, all patients had severe ear pain, 68% tympanic membrane perforation and discharge, 43% fever, and 43% vertigo. In pure-tone audiometry, there was usually a marked mixed hearing loss at presentation. There was a significant recovery in both air and bone conduction thresholds; the pure tone average improvement from presentation was 32.3 ± 14.8 dB. Rapid strep tests (RST) proved to be more sensitive than bacterial culture in identifying GAS as a cause of AOM/AM.

Conclusion: GAS AOM/AM has a rapid onset. Hearing loss usually includes a sensorineural component, which is usually reversible with adequate treatment. RST seems to be useful in detecting GAS from middle ear discharge.

Level of Evidence: 4.

Keywords: acute mastoiditis, acute otitis media, group A beta-hemolytic streptococcus, health-related quality of life, Streptococcus pyogenes
INTRODUCTION

Group A beta-hemolytic streptococcus (GAS; *Streptococcus pyogenes*) is a common pathogen, responsible for a variety of diseases.\(^1,2\) GAS causes 5% to 10% of pharyngotonsillitis cases in adults and up to 37% in children older than 5 years; it also causes cutaneous infections.\(^3,4\) GAS can lead to invasive infections such as bacteremia, streptococcal toxic shock syndrome, pneumonia, osteomyelitis, mastoiditis, and necrotizing fasciitis. The incidence of invasive GAS infection in developed countries is 2.3 to 6.2/100 000 and the fatality rate for streptococcal toxic shock syndrome is 30% to 60%.\(^2,5-12\) Post-streptococcal autoimmune sequelae leading to rheumatic fever, rheumatic heart disease, arthritis, and glomerulonephritis still occur even after the discovery of penicillin.\(^6,13,14\)

Acute otitis media (AOM) is a common reason for seeking medical attention with overall global estimated incidence rate at 10.8 out of 100 yearly\(^15\) with 51% of these occurring in children under 5 years of age.\(^16\) Studies of microbial etiology demonstrate that *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Moraxella catarrhalis* are significant causes of AOM, albeit the prevalence of *S. pneumoniae* has decreased since the introduction of pneumococcal conjugate vaccines.\(^15,17\) GAS is estimated to cause 2-3% of AOM cases in children.\(^17\) Acute mastoiditis (AM), the most common potentially serious complication of AOM, remains quite rare. Its microbial etiology is usually *S. pneumoniae* or GAS,\(^18,19\) where GAS is the causative agent in 14% to 53% of hospitalized AOM/AM cases.\(^18,20,21\)

The incidence of invasive GAS infections, including severe AOM and AM, has been shown to fluctuate with a cycle of approximately 7 to 8 years.\(^5,21-23\) In Finland, the number of invasive GAS infections increased significantly in 2017 compared to previous years (Figure 1).\(^24\) During 2017 and 2018, we also noticed a marked increase in patients with severe GAS AOM/AM needing hospital care. Since GAS and diseases caused by it are not fading away in the near future, we set out to describe the current incidence, diagnostics, disease course, and outcome of severe GAS AOM/AM in our hospital setting with special attention given to hearing outcomes. Although many GAS AOM/AM patients show marked sensorineural hearing loss (SNHL) at presentation, hearing outcomes have not been described in detail in the literature.\(^25-27\) Also, we wanted to describe how rapid antigen detection tests (rapid strep tests [RSTs]) from middle ear secretion may be used in conjunction with the bacterial culture to expedite diagnostics.

MATERIALS AND METHODS

2.1 Study design and ethics

This study was based on retrospective evaluation of patient records, with a later follow-up based on a health-related quality of life (HRQoL) survey. The study was approved by the Helsinki University Hospital Ethical committee (no 1121/2020) and had study permissions from the institutional research board (§73 HUS/66/2018 30.8.2018 and 67§ HUS/1121/2020 15.04.2020).
2.2 | Patients

This study included 206 patients requiring hospitalization at the Department of Otorhinolaryngology in Helsinki University Hospital, during 2013 and 2018 for AOM/AM and complications caused by them. The Helsinki University Hospital has 1.7 million catchment area and is the only on-call ear, nose, and throat clinic in the area meaning all ear infections that require hospitalization are treated here. The exclusion criterion was trauma as the cause of the infection and one patient was excluded on this basis. Of these 205 cases, GAS was a causative agent in 60 patients. To determine the incidence of GAS AOM/AM requiring hospitalization, we also used data from 2002 to 2012 from earlier publications. Between 2002 and 2018, in total 314 adults and 149 children were hospitalized for AOM/AM. Of these, 76 adults (24%) and 27 (18%) children had GAS AOM/AM. For the detailed analysis part of this study, we concentrated on the 37 patients treated during the last GAS epidemic between 2017 and 2018, since the diagnostic workup and treatment protocols were uniform in our department over that period.

2.3 | Definitions and treatments

The samples for microbiological analysis were taken from every patient at presentation from the middle ear secretion after tympanocentesis, or in the case of spontaneously ruptured tympanic membrane (TM), from the external auditory canal. Usually both bacterial culture and RSTs (Quicker Dipstick Strep A test by Quidel, San Diego, California) were performed. Either positive bacterial culture (predominant or pure growth of GAS) or positive RST from middle ear secretion was considered GAS AOM/AM in this study. The diagnosis of AM was based on the clinical picture where otomicroscopy-confirmed AOM was combined with retroauricular pain, erythema and/or tenderness and/or protrusion of the auricle. Chronic otitis media (COM) refers to an inflammatory condition of the middle ear and mastoid cavity that has persisted for at least 3 months. Recurrent acute otitis media (RAOM) is defined as having at least three episodes of AOM in a period of 6 months, or four or more episodes in 12 months. Fever was interpreted as axillary temperature ≥37.8°C. GAS patients were treated based on our clinical care guidelines. These included proper ventilation provided by spontaneous TM perforation, large tympanocentesis, or (in most cases) tympanostomy tube placement at presentation, intravenous antibiotics (primarily benzylpenicillin, in combination with clindamycin in more severe cases), ear drops containing ciprofloxacin and fluocinolone acetonide, and systemic methylprednisolone. Surgical treatment (tympanomastoidectomy) was performed if needed, based on individual evaluation.

2.4 | Pure tone audiometry

Of the 37 patients treated as inpatients during 2017 and 2018, 24 patients (65%) had had their hearing examined within 1 day of hospitalization and had received a second hearing examination after at least 21 days of follow-up. These patients were selected for audiologic analysis. Pure tone audiograms were extracted from a clinical audiology database (AuditBase, Auditdata, Denmark) using an SQL script (SQLTalk, Gupta Technologies, California). Air conduction (AC) thresholds were collected at 0.125, 0.25, 0.5, 1, 2, 4, 6, and 8 kHz frequencies and bone conduction (BC) thresholds for 0.25, 0.5, 1, 2, and 4 kHz frequencies. Due to difficulties in acoustic calibration, BC thresholds are typically not measured above 4 kHz. BC is not routinely measured at all in any given frequency if AC is normal (≤20 dB HL). Therefore, in a variant on analysis, we combined the audiometric information containing both the AC and BC thresholds as “minimum of AC/BC thresholds,” where AC and BC thresholds were compared individually for each frequency, and if measured, the BC was chosen for further analysis. As customary to Finland, pure tone average (PTA) was computed as a mean of AC thresholds (PTAair) and a mean of the minimum of AC/BC (PTAmin) thresholds at 0.5, 1, 2, and 4 kHz.

2.5 | HRQoL

The HRQoL was investigated using an otology-specific HRQoL instrument EOS-16 and a generic HRQoL survey 15D. The 16-point EOS-16 covers ear symptoms, hearing, balance, psychosocial impact, and need for care. The surveys were sent to Finnish-speaking adult patients whose addresses were known (n = 22) for completion 1.5 to 3 years after the onset of infection.

2.6 | Statistics

Statistical analyses were performed using IBM SPSS Statistics for Macintosh version 25 (Armonk, New York), Microsoft Excel version 16.22 (Redmond, Washington) and Prism 8 (GraphPad, San Diego, California). Graphs were made with Prism and Matlab version R2018a (Natick, Massachusetts). The level of significance was set at P < .05. Two-way ANOVA with Sidak’s multiple comparison test was used to analyze the audiometric data.

3 | RESULTS

3.1 | Yearly incidence of hospitalized GAS AOM/AM during 2003 and 2018

The incidences of severe AOM/AM necessitating hospitalization at our department and bacteremia caused by GAS in the Helsinki University hospital district are presented in Figure 1. The graph demonstrates fluctuations in the number of GAS infections. Between the invasive GAS epidemics, the annual average for GAS OMA/AM patients needing inpatient care is about five cases, with cases occurring more frequently during the summer months (June-August, data not shown). During the epidemic of 2017 and 2018, there was a clear correlation between incidences of GAS bacteremia in the Helsinki University hospital district and severe GAS AOM/AM treated in our
3.2 | Patient demographics

The cohort included 37 patients requiring inpatient care. The majority (78%) were adults (Table 1). None of the patients had COM and none had undergone previous ear surgery (except for possible grommets for treatment of earlier ear disease). Seven patients (19%; three adults and four children) had a history of RAOM.

3.3 | Findings at presentation

Time from the onset of any ear symptom suggestive of infection to the first doctor’s appointment was usually short, 1.3 ± 2.0 (mean ± SD) days (Table 1). Time from the symptom onset to hospitalization was 4.0 ± 4.2 days. Ten (27%) patients were hospitalized less than 24 hours from the onset of symptoms, demonstrating the very rapid progress of the disease in many cases. The majority (68%) had TM perforation and discharge. Based on clinical judgment, 23 (62%) had AOM and 14 (38%) AM. One elderly patient had an intracranial abscess as a complication of mastoiditis.

### Table 1 Patient demographics, and clinical and laboratory findings at presentation

|                          | All (n = 37)         | Adults (n = 29)         | Children (n = 8)          |
|--------------------------|----------------------|-------------------------|---------------------------|
| **Age (years), mean ± SD (range)** | 38.8 ± 21.2 (4.1-85.9) | 45.7 ± 17.9 (17.6-85.9) | 12.0 ± 4.3 (4.1-15.4)    |
| **Gender:** Female (%)   | 21 (57)              | 17 (59)                 | 4 (50)                    |
| **Affected ear**         |                      |                         |                           |
| Left (%)                 | 21 (57)              | 18 (62)                 | 3 (37)                    |
| Right (%)                | 14 (38)              | 9 (31)                  | 5 (62)                    |
| Both (%)                 | 2 (5)                | 2 (6)                   | 0 (0)                     |
| **Acute otitis media (%)** | 23 (62)              | 19 (66)                 | 4 (50)                    |
| **Acute mastoiditis (%)** | 14 (38)              | 10 (34)                 | 4 (50)                    |
| **Delay to GP (days), mean ± SD (range)** | 1.3 ± 2.0 (0-10) | 1.4 ± 2.1 (0-10)       | 0.8 ± 1.0 (0-3)           |
| **Delay to hospital (d)** | 4.0 ± 4.2 (0-20)     | 3.9 ± 4.4 (0-20)       | 4.3 ± 2.9 (1-10)          |
| **Previous ear condition (%)** |                      |                         |                           |
| RAOM                     | 7 (19)               | 3 (10)                  | 4 (50)                    |
| SOM                      | 0 (0)                | 0 (0)                   | 0 (0)                     |
| COM                      | 0 (0)                | 0 (0)                   | 0 (0)                     |
| Previously operated ear  | 0 (0)                | 0 (0)                   | 0 (0)                     |
| **Signs and symptoms (%)** |                      |                         |                           |
| TM perforation and discharge | 25 (68)              | 18 (62)                 | 7 (87)                    |
| Retroauricular pain      | 7 (19)               | 3 (10)                  | 4 (50)                    |
| Retroauricular erythema  | 8 (22)               | 0 (0)                   | 8 (100)                   |
| Protruding ear           | 1 (3)                | 0 (0)                   | 1 (12)                    |
| Retroauricular swelling  | 1 (3)                | 0 (0)                   | 1 (12)                    |
| Fever                    | 16 (43)              | 12 (41)                 | 4 (50)                    |
| Vertigo                  | 16 (43)              | 14 (48)                 | 2 (25)                    |
| Nystagmus                | 7 (19)               | 7 (24)                  | 0 (0)                     |
| Facial nerve paresis     | 2 (5)                | 2 (6)                   | 0 (0)                     |
| **Laboratory findings**  |                      |                         |                           |
| CRP (mg/L) mean ± SD (range) | 117 ± 91 (3-341)   | 119 ± 93 (3-341)       | 107 ± 87 (4-234)          |
| Leukocytes 10⁹/L         | 11.8 ± 3.5 (5.4-19.7) | 10.9 ± 3.1 (5.4-17.1)  | 13.2 ± 4.3 (6.1-18.7)     |
| GAS positive ear discharge | 37(100)             | 29 (100)                | 8 (100)                   |
| GAS culture pos, n = 37 taken (%) | 30 (81)             | 22 (76)                 | 8 (100)                   |
| RST pos, n = 30 taken (%) | 29 (97)              | 21 (95)                 | 8 (100)                   |
| Blood culture taken (%)  | 4 (11)               | 3 (10)                  | 1 (12)                    |
| Blood culture positive GAS (%) | 2 (5)               | 2 (7)                   | 0 (0)                     |

Note: Children 0 to <16 years old.
Abbreviations: COM, chronic otitis media; GAS, group A beta-hemolytic streptococcus; GP, general practitioner; RAOM, recurrent acute otitis media; RST, rapid strep test; SOM, serous otitis media; TM, tympanic membrane.
Blood culture was taken from four (11%) patients (three adults and one children) and was GAS positive for two (5%) adult patients. Bacterial culture was taken from the ear discharge of all patients at presentation. Thirty samples (81%) were GAS positive (22/29 adults and 8/8 children). The RST was taken at presentation from 30 patients (22 adults and 8 children), and was positive in all but one adult, who had a positive GAS in bacterial culture from ear discharge (Tables 1 and 2).

3.4 | Treatment

Hospital treatment algorithm was followed (Table 3). Four adult patients had a large TM perforation as a result of the current infection, and thus did not need additional ventilation provided by the grommet. None had confirmed or suspected perforation prior to the current infection. During their hospital stay, six (16%) patients needed tympanomastoidectomy due to the infection being refractory to conservative treatment. Four of the six tympanomastoidectomies were performed within 24 hours of hospitalization. Two of the six patients experienced mastoidectomy on the third and fourth days of treatment due to increased pain. AOM patients were hospitalized on average for 3.8 ± 1.9 (range, 1-8) days. AM patients were hospitalized on average for 7.0 ± 3.4 (3-12) days (without tympanomastoidectomy) or 7.2 ± 4.8 (3-15) days (with tympanomastoidectomy). There were no differences in the length of hospital stay between adults and children.

3.5 | Audiological findings at presentation

Two patients were known to have moderate SNHL (PTA ≥ 50 dB HL) before GAS infection. The other patients’ hearing had not been examined prior to infection or it was potentially tested as part of national screening studies (school, military service, and occupational), but no previous hearing loss was reported.

Audiological findings within 1 day of hospital arrival are presented in Figure 2. There was considerable variation between individuals in AC thresholds. In most cases, higher frequencies were more affected than low and mid frequencies. At presentation, the PTA\textsubscript{ave} was 50.3 ± 19.4 dB HL. The findings in AC thresholds are not surprising, as middle ear secretion and TM perforation are known to cause conductive hearing loss (CHL). However, our main interest was in the possible SNHL. Individual minimum AC/BC thresholds are shown in Figure 2B. At presentation, the PTA\textsubscript{min} was 28.3 ± 15.4 dB

| TABLE 2 | Comparison of group A beta-hemolytic streptococcus (GAS) bacterial culture and rapid strep test (RST) results from ear discharge |
| n = 37 | Culture positive | Culture negative |
| RST positive | 29 | 7 |
| RST negative | 1 | 0 |
| RST not taken | 7 | 0 |

Note: Bacterial culture was taken from all 37 patients.

| TABLE 3 | Treatments given and length of hospital stay |
| In total (n = 37) | Adults (n = 29) | Children (n = 8) |
| Intravenous antibiotics (%) | 37 (100) | 29 (100) | 8 (100) |
| Benzylpenicillin and clindamycin | 20 (54) | 18 (62) | 2 (25) |
| Benzylpenicillin | 2 (5) | 0 (0) | 2 (25) |
| Cefuroxime | 10 (27) | 7 (24) | 3 (36) |
| Cefuroxime and clindamycin | 3 (8) | 2 (7) | 1 (13) |
| Ceftriaxone | 1 (3) | 1 (3) | 0 (0) |
| Piperacillin/tazobactam | 1 (3) | 1 (3) | 0 (0) |
| Local antibiotic/corticosteroid drops | 37 (100) | 29 (100) | 8 (100) |
| Systemic corticosteroid | 33 (89) | 26 (89) | 7 (87) |
| Temporal bone CT taken | 13 (35) | 12 (41) | 1 (13) |
| MRI taken | 1 (3) | 1 (3) | 0 (0) |
| Tympanostomy tubes at arrival | 33 (89) | 25 (86) | 8 (100) |
| Mastoidectomy during hospital stay | 6 (16) | 5 (17) | 1 (12) |
| Later mastoidectomy | 1 (3) | 1 (3) | 0 |
| Length of hospital stay (d) | | | |
| AOM, mean ± SD (range) | 3.8 ± 1.9 (1-8) | 3.8 ± 1.8 (1-8) | 3.9 ± 2.2 (1-8) |
| AM without mastoidectomy | 7.0 ± 3.4 (3-12) | 7.0 ± 3.4 (3-12) | - |
| AM, with mastoidectomy | 7.2 ± 4.8 (3-15) | 7.5 ± 5.4 (3-15) | 6 (n = 1) |

Note: The presented antibiotic treatment is based on use ≥50% of the time spent on the ward. Length of hospital stay, mean ± SD (range). Children 0 to <16 years old.
Abbreviations: AOM, acute otitis media; AM, acute mastoiditis; CT, computed tomography; Mastoidectomy, tympanomastoidectomy.
Fourteen (58%) patients had SNHL within our criterion (PTA_{min} > 20 dB HL, Figure 2B, Table 4). At 4 kHz, 22 (92%) patients had elevated (>20 dB HL) AC thresholds and the mean AC threshold was 63.8 ± 25.4 dB HL. At 4 kHz, 18 (75%) patients had elevated minimum AC/BC thresholds indicating SNHL, and the mean of minimum of AC/BC thresholds was 36.0 ± 18.2. These results suggest that the conductive component of the hearing loss was on average 27.7 dB HL at 4 kHz. At 6 and 8 kHz, the BC thresholds were unavailable, but the means of AC thresholds were 72.3 ± 25.8 and 75.2 ± 22.3 dB HL, respectively. If we suggest that the CHL component stays at the same level at these higher frequencies as it does at 4 kHz, it may be assumed that BC would average 45 dB HL at these higher frequencies.

### 3.6 Outcome

One patient (81 years old) died of GAS sepsis and multi-organ failure at day 3 of the treatment. All other patients survived, having a mean follow-up of 83 ± 72 (8-229) days. After follow-up, all patients had recovered from vertigo, nystagmus, facial paresis, and retroauricular pain. None of the patients had recurrent AOM/AM. One adult, who had undergone tympanomastoidectomy during the hospital stay, developed COM and needed a revision tympanomastoidectomy. One child was diagnosed with otitis media with effusion during the follow-up visit (grommet was blocked).

The audiometric results after follow-up (mean 103 ± 69 [29-229] days, n = 24) are presented in Figure 3 and Table 4. During follow-up, both AC and minimum of AC/BC thresholds recovered markedly. The positive changes were more pronounced in the higher frequencies, where the original hearing loss had been more profound. The average improvement in AC thresholds at all frequencies was 30.2 ± 13.9 dB HL (P < .001), where statistically significant improvement occurred in all frequencies but 125 Hz. The average improvement at all frequencies in minimum of AC/BC thresholds was 19.1 ± 10.3 dB HL (P < .0001), the difference being statistically significant in frequencies between 2 and 8 kHz.

After follow-up, PTA_{air} was 18.0 ± 13.6 dB HL, and the improvement from presentation was 32.3 ± 14.8 dB HL (P < .001; Figure 3A). After follow-up, PTA_{min} was 13.7 ± 10.8 dB HL (Figure 3C), which had improved on average by 14.6 ± 11.8 dB HL (P < .0001) from presentation. Altogether, these results demonstrate that the original measured 36 dB SNHL at 4 kHz as well as the estimated 45 dB SNHL at 6 and 8 Hz were in most cases reversible (Table 4).
To find out the long-term impact of GAS AOM/AM on the HRQoL, 22 patients were sent EOS-16 and 15D questionnaires. Thirteen patients (59%) returned the questionnaires with a mean follow-up time of 2.3 ± 0.38 (1.9-3.0) years. The maximum handicap score in EOS-16 is 64. The mean score in our patients was 12.6 ± 13.7 (0-44). Three patients (23%) had EOS-16 scores 20 or above, which describes significant impairment in quality of life. One patient, who developed COM during the follow-up, scored 37 in EOS-16. Two patients with no objective residual symptoms other than SNHL, scored 44 and 20 in EOS-16. The generic 15D score was 0.94 ± 0.05 (0.83-1.0), where 1 means asymptomatic condition and 0 worst possible QoL.

4 | DISCUSSION

An exceptionally high incidence of GAS AOM/AM was observed in Finland during 2017 and 2018. At the same time, the number of GAS bacteremia cases increased significantly, as the emm1 type emerged predominantly. Epidemiology shows that GAS AOM/AM cases usually increase in 7 to 8-year periods (Figure 1). The last epidemic, with 37 cases treated in a single institution with uniform clinical guidelines of care, offered an exceptional opportunity to characterize severe GAS AOM/AM and its outcome.

The leading clinical signs of GAS AOM/AM are ear pain, discharge, and rapid overall progression. This is rather atypical for AOM/AM caused by other causative agents, where the disease progression usually takes longer, with the possible exception of S. pneumoniae infections. In the most typical case, GAS AOM/AM presents in a previously healthy ear of a healthy person (Table 1). Although the outcomes of patients in this study were quite good, development of permanent severe SNHL or deafness remains possible, especially with insufficient treatment.

The causative agents of AOM leading to complications differ significantly between countries. In Finland, S. pneumoniae and GAS are
the most common findings in complicated situations, whereas in Brazil, Pneumococcus, Haemophilus, and Staphylococcus species were the most common microorganisms in AOM with complications. However, despite the health care resources in the country of residence, AOM/AM can still be disabling and fatal worldwide.

We tested the use of RST to analyze samples from middle ear effusion, although the use of RST by manufacturer is limited to pharyngeal sampling. In our series, bacterial culture was taken from every inpatient. In seven cases, RST was positive despite culture resulting in “no growth.” All of these seven cases had ongoing oral antibiotic treatment at the time of the microbiological sample, possibly explaining the findings. On the other hand, only one patient was RST negative, whereas the bacterial culture was positive for GAS. We consider the RST a very promising tool in rapid diagnostics. RST is easy-to-use, non-invasive, and quick. We, however, acknowledge that more information is needed to verify the reliability of RST in the context of middle ear GAS infections. The off label use of RST has been reported in vaginal samples, but to our knowledge, it has not been reported in the context of ear discharge previously.

During the GAS epidemic between 2017 and 2018, treatment algorithm was used in GAS AOM/AM: most patients received a tympanostomy tube or had large TM perforation at arrival; intravenous antimicrobial medication, primarily penicillin, when the pathogen (GAS) was confirmed and addition of clindamycin for more severe cases; systemic corticosteroid (methylprednisolone); and eardrops (corticosteroid and ciprofloxacin). The typical course of disease, with this treatment, was as follows: The infection usually started to resolve within the first couple of days; the infection subsided, the purulent secretion stopped, but abundant pulsating serous secretion continued. Next, the ear pain was reduced, vertigo reduced, and possible mastoid pain relieved. With ear secretion clearly diminishing, the patient could be discharged. However, the disease was refractory to this conservative treatment regimen in 16% of patients, who needed tympanomastoidectomy to recover. Whether or not the tympanomastoidectomy was performed had no effect on the time of hospitalization. Patients without mastoiditis had a shorter hospitalization period. In previous publications, there are no major differences in AOM/AM hospitalization times between different pathogens, but the hospitalization for S. pneumoniae was the longest.

The patients' hearing recovery was unexpectedly good, considering the SNHL at presentation (Figures 2 and 3; Table 4). Although most patients reported being relatively asymptomatic at their follow-up visit, they did have some residual symptoms as measured by the EOS-16 after 1.5 to 3 years. Although only two patients had no improvement at all in the 3-months follow-up, 79% of the patients had normal hearing after follow-up. One explanation of the SNHL reversibility might be vasospasm caused by inflammation. Vasospasm in turn may cause temporary hair cell dysfunction secondary to temporary ischemia instead of hair cell loss. If inflammation is relieved soon enough, hair cell function may recover. Alternatively, it is possible that direct irritation of the oval and round window membrane with cytokines or other inflammation mediators leads to temporary SNHL. The fact that the higher frequencies located at the basal part of the cochlea are usually the most affected supports this hypothesis of local inflammation. In this hypothesis, the transient hair cell dysfunction would be restored when inflammation is relieved.

5 | CONCLUSIONS

Severe GAS AOM/AM typically has a very rapid onset with severe symptoms. Hearing loss is common and most often includes a sensorineural component. However, the hearing loss is usually reversible. RSTs seem to be useful in detecting GAS in middle ear discharge. Despite the rapid onset and initial aggressive behavior of GAS AOM/AM, its outcome with the current treatment is usually satisfactory.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

ORCID

Juha T. Laakso https://orcid.org/0000-0002-5561-9535
Anu Laulajainen-Hongisto https://orcid.org/0000-0001-5109-6944

BIBLIOGRAPHY

1. Brouwer S, Barnett TC, Rivera-Hernandez T, Rohde M, Walker MJ. Streptococcus pyogenes adhesion and colonization. FEBS Lett. 2016;590(21):3739-3757. https://doi.org/10.1002/1873-3468.12254
2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685-694. https://doi.org/10.1016/s1473-3099(05)70267-x
3. Banerjee D, Michael J, Schmitt B, et al. Multicenter clinical evaluation of Revogene Strep A molecular assay for detection of Streptococcus pyogenes from throat swab specimens. J Clin Microbiol. 2020;58(7):e01775-19. https://doi.org/10.1128/jcm.01775-19
4. Karakonstantis S. Is coverage of S. aureus necessary in cellulitis/erysipelas? A literature review. Infection. 2020;48(2):183-191. https://doi.org/10.1007/s10151-019-01382-7
5. Nelson GE, Pondo T, Toews KA, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012. Clin Infect Dis. 2016;63(4):478-486. https://doi.org/10.1093/cid/ciw248
6. Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A streptococcus. Clin Microbiol Rev. 2014;27(2):264-301. https://doi.org/10.1128/CMR.00101-13
7. Sanchez-Encinales V, Ludwig G, Tamayo E, Garcia-Arenzana JM, Munoz-Almagro C, Montes M. Molecular characterization of Streptococcus pyogenes causing invasive disease in pediatric population in Spain: a 12-year study. Pediatr Infect Dis J. 2019;38(12):1168-1172. https://doi.org/10.1097/INF.0000000000002471
8. Waddington CS, Snelling TL, Carapetis JR. Management of invasive group A streptococcal infections. J Infect. 2014;69(suppl 1):S63-S69. https://doi.org/10.1016/j.jinf.2014.08.005
9. Ekelund K, Skinhøj P, Madsen J, Konradsen HB. Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study. J Clin Microbiol. 2005;43(4):1789-1796. https://doi.org/10.1128/jcm.43.4.1789-1796.2005
10. Darenberg J, Luca-Harari B, Jasir A, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis. 2007;45(4):450-458. https://doi.org/10.1086/519936
11. O’Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. Clin Infect Dis. 2002;35(3):268-276. https://doi.org/10.1086/341409
12. Lepoutre A, Doloy A, Bidet P, et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol. 2011;49(12):4094-4100. https://doi.org/10.1128/jcm.00700-11

13. Cunningham MW. Post-streptococcal autoimmune sequelae: rheumatic fever and beyond. In: Ferretti JJ, Stevens DL, Fischetti VA, eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK):University of Oklahoma Health Sciences Center; 2016.

14. Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2018;392(10142):161-174. https://doi.org/10.1016/s0140-6736(18)30999-1

15. Schilder AG, Chonmaitree T, Cripps AW, et al. Otitis media. Nat Rev Dis Primers. 2016;2:16063. https://doi.org/10.1038/nrdp.2016.63

16. Monasta L, Ronfani L, Marchetti F, et al. Burden of disease caused by otitis media: systematic review and global estimates. PLoS One. 2012;7(4):e36226. https://doi.org/10.1371/journal.pone.0036226

17. Coker TR, Chan LS, Newberry SJ, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA. 2010;304(19):2161-2169. https://doi.org/10.1001/jama.2010.1651

18. Mansour T, Yehudai N, Tobia A, et al. Acute mastoiditis: 20 years of experience with a uniform management protocol. Int J Pediatr Otorhinolaryngol. 2019;125:187-191. https://doi.org/10.1016/j.ijpolor.2019.07.014

19. Balsamo C, Biagi C, Mancini M, Corsini I, Bergamaschi R, Lanari M. Acute mastoiditis in an Italian pediatric tertiary medical center: a 15-year retrospective study. Ital J Pediatr. 2018;44(1):71. https://doi.org/10.1186/s13052-018-0511-z

20. Laulajainen-Hongisto A, Aarnisalo AA, Jero J. Differentiating acute mastoiditis from acute otitis media. Curr Opin Infect Dis. 2011;24(3):196-202. https://doi.org/10.1097/QCO.0b013e32834587fe

21. Laulajainen-Hongisto A, Jero J, Markkola S, Saat R, Aarnisalo AA. Severe acute otitis media and acute mastoiditis in adults. J Int Adv Otol. 2016;12(3):224-230. https://doi.org/10.5152/iao.2016.2620

22. Powis J, McGeer A, Duncan C, et al. Prevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother. 2005;49(5):2130-2132. https://doi.org/10.1128/aac.49.5.2130-2132.2005

23. Lysneyk NN, Lawson RA, Sriskandan S. New understandings in Streptococcus pyogenes. Curr Opin Infect Dis. 2011;24(3):196-202. https://doi.org/10.1097/QCO.0b013e32834587fe

24. Vilhonen J, Vuopio J, Vahberg T, Gröndahl-Yli-Hannukela K, Rantakokko-Jalava K, Oksi J. Group A streptococcal bacteremias in Southwest Finland 2007-2018: epidemiology and role of infectious diseases consultation in antibiotic treatment selection. Eur J Clin Microbiol Infect Dis. 2020;39:1339-1348. https://doi.org/10.1007/s10096-020-03851-6

25. Haas L, van der Ploeg R, Quak J, Burgmans J, Otten M. A young man with severe and disabling complications of septic shock. Am J Crit Care. 2015;24(5):450-452.

26. Haghiya H, Otsuka F. Group A streptococcal meningitis in a patient with palmoplantar pustulosis. Intern Med. 2013;52(23):2675-2678.

27. Fearrington S, Weider D. Sensori-neural hearing loss in acute otitis media due to beta-hemolytic streptococcus successfully treated with penicillin and prednisone. Ear Nose Throat J. 1991;70(8):513-519.

28. Laulajainen-Hongisto A, Aarnisalo AA, Jero J. Differentiating acute otitis media and acute mastoiditis in hospitalized children. Curr Allergy Asthma Rep. 2016;16(10):72. https://doi.org/10.1007/s11882-016-0654-1

29. Laakso JT, Silvola J, Hirvonen T, et al. Development of otology specific outcome measure: ear outcome survey-16 (EOS-16). J Otol. 2021;16:150-157. https://doi.org/10.1016/j.joto.2021.01.003

30. Sintonen H. The 15-D measure of health related quality of life: reliability, validity and sensitivity of its health state descriptive system. Working Paper 41. January 1, 1994.

31. Infectious Diseases in Finland 2017 (Finnish National Institute for Health and Welfare); 2018.

32. Jespersen MG, Lacey JA, SYC T, Davies MR. Global genomic epidemiology of Streptococcus pyogenes. J Infect. 2020;86:104609. https://doi.org/10.1016/j.jinf.2020.104609

33. Penido Nde O, Chandrasekhar SS, Borin A, Maranhão AS, Gurgel Testa JR. Complications of otitis media - a potentially lethal problem still present. Braz J Otorhinolaryngol. 2016;82(3):253-262. https://doi.org/10.1016/j.bjorl.2015.04.007

34. Norowitz HL, Morello T, Kupfer HM, Kohlhoff SA, Smith-Norowitz TA. Association between otitis media infection and failed hearing screenings in children. PLoS One. 2019;14(2):e0212777. https://doi.org/10.1371/journal.pone.0212777

35. Van Limbergen J, Kalma P, Taheri S, Beattie TF. Streptococcus a in paediatric accident and emergency: are rapid streptococcal tests and clinical examination of any help? Emerg Med J. 2006;23(1):32-34. https://doi.org/10.1136/emj.2004.022970

36. Hamilton SM, Stevens DL, Bryant AE. Pregnancy-related group A streptococcal infections: temporal relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin Infect Dis. 2013;57(6):870-876. https://doi.org/10.1093/cid/cit282

37. Eisenhut M. Evidence supporting the hypothesis that inflammation-induced vasospasm is involved in the pathogenesis of acquired sensorineural hearing loss. Int J Otorhinolaryngol. 2019;2019:4367240. https://doi.org/10.1155/2019/4367240

38. Kalinec GM, Lomberk G, Urrutia RA, Kalinec F. Resolution of cochlear hearing loss in chronic evidence supporting the hypothesis that inflammation-induced vasospasm is involved in the pathogenesis of acquired sensorineural hearing loss. Int J Otorhinolaryngol. 2019;2019:4367240. https://doi.org/10.1155/2019/4367240

39. Kalinec GM, Lomberk G, Urrutia RA, Kalinec F. Resolution of cochlear hearing loss in chronic evidence supporting the hypothesis that inflammation-induced vasospasm is involved in the pathogenesis of acquired sensorineural hearing loss. Int J Otorhinolaryngol. 2019;2019:4367240. https://doi.org/10.1155/2019/4367240

How to cite this article: Laakso JT, Rissanen V, Ruotsalainen E, et al. Severe acute otitis media and mastoiditis caused by group A beta-hemolytic streptococcus. Laryngoscope Investigative Otolaryngology. 2021;6(5):1158-1166. doi:10.1002/io.2659